Bile duct cancer study seeks clues in genes to predict treatment success
NCT ID NCT06648057
First seen Mar 23, 2026 · Last updated May 09, 2026 · Updated 8 times
Summary
This study is for people with advanced biliary tract cancer (a type of bile duct cancer) who are scheduled to receive a combination of two drugs, lenvatinib and pembrolizumab. Researchers want to find genetic markers in blood and tumor samples that might predict how well a person responds to this treatment. The goal is to better understand which patients benefit most, not to test a new treatment directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bundang CHA Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.